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Edited by Giulio Superti-FurgaAbstract C1q, the binding subunit of the C1 complex of com-
plement, is an archetypal pattern recognition molecule known
for its striking ability to recognize a wide variety of targets,
ranging from pathogenic non self to altered self. DNA is one
of the C1q ligands, but the precise region of C1q and the DNA
motifs that support interaction have not been characterized
yet. Here, we report for the ﬁrst time that the peripheral globular
region of the C1q molecule displays a lectin-like activity, which
contributes to DNA binding through interaction with its
deoxy-D-ribose moiety and may participate in apoptotic cell
recognition.
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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recognition1. Introduction
C1q is well characterized for its role as the recognition pro-
tein of the C1 complex and its ability to trigger activation of
the classical complement pathway [1,2]. Over the past years,
there has been increasing evidence that, owing to its heterotri-
meric nature and its oligomeric structure, this protein plays a
crucial role in the detection and scavenging of a wide variety
of potentially noxious substances ranging from pathogenic
non self to altered self, such as b-amyloid ﬁbrils, the patholog-
ical form of the prion protein, necrotic and apoptotic cells, or
modiﬁed forms of the low-density lipoprotein [3–8].
It is well documented that the complement activating func-
tion of C1q is mediated through binding of its globular periph-
eral regions to targets (pathogen surfaces and IgG- or IgM-
containing immune complexes) [1,2,9]. The nature of the C1q
binding sites and the mechanisms involved in the recognition
of altered self structures are still debated even though the het-
erotrimeric structure of its globular regions (GRs) is likely aAbbreviations: EMSA, electrophoretic mobility shift assay; GlcNAc,
N-acetyl glucosamine; GalNAc, N-acetyl galactosamine; GR, C1q
globular region; SPR, surface plasmon resonance
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doi:10.1016/j.febslet.2008.08.001key to the versatility of the C1q recognition properties [10].
The GRs are involved in the sensing of ‘‘eat me’’ signals ex-
posed at the apoptotic cell surface [7], and it was recently dem-
onstrated that the polar head of phosphatidylserine (PS) is one
of the C1q GR ligands [11]. Calreticulin, another known C1q
ligand, has been proposed recently to play a central role in
apoptotic cell clearance [12], but how C1q is involved in this
process remains to be fully elucidated at the molecular level.
It has also been reported by Elward et al. [13] that C1q recog-
nizes self DNA accessible early on apoptotic cells, before PS
becomes exposed. However, the precise region of C1q involved
in DNA binding is a matter of controversy, since both the col-
lagen-like region and the GR have been implicated [14–18]. On
the other hand, the DNA motifs that support interaction with
C1q have not been characterized yet. Nevertheless, several
observations support the hypothesis that C1q may exhibit car-
bohydrate binding ability, suggesting that it could recognize
DNA through its sugar moiety. Thus, it was shown early that
synthetic polysaccharides are able to mediate C1 activation
through C1q binding [19]. As reported more recently, C1q
binds to an abundant urine glycoprotein (Tam-Horsfall pro-
tein) and recognition of this protein by C1q is markedly re-
duced after removal of its carbohydrates by glycosidases
[20,21]. Phylogenetic studies also indicate that the C1q ortho-
logue in lamprey, the most primitive vertebrate, is an N-acetyl
glucosamine (GlcNAc) binding lectin that plays an important
role in innate immunity [22].
The purpose of this study was to further investigate the lec-
tin-like activity of human C1q using surface plasmon reso-
nance spectroscopy as well as its possible implications in
DNA and apoptotic cell recognition.2. Materials and methods
2.1. Proteins and carbohydrates
C1q was puriﬁed from human serum and its GRs were prepared and
quantiﬁed as described previously [5,23]. Carbohydrates and DNAse
were obtained from Sigma–Aldrich. BSA glycoconjugates were ob-
tained from Dextra laboratories. The concentrations of GlcNAc-
BSA and GalNAc-BSA were determined using Mr values of 84488
and 79177, respectively.
2.2. Cells
HeLa cells (ATCC # CCL-2) were cultivated in Glutamax D-MEM
medium (Invitrogen, Cergy Pontoise, France) supplemented with 10%
(v/v) foetal calf serum, 2.5 U/ml penicillin and 2.5 lg/ml streptomycinublished by Elsevier B.V. All rights reserved.
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ously [11]. Brieﬂy, cells (3 · 106) were grown in sterile dishes overnight
to 60–80% conﬂuence and exposed to 1000 mJ/cm2 UV-B irradiation
at 312 nm in fresh D-MEM medium. Cells were then incubated under
5% CO2 at 37 C for 2 h.
2.3. Surface plasmon resonance (SPR) spectroscopy
Analyses were carried out on a BIAcore 3000 or a BIAcore X instru-
ment (BIAcore, GE Healthcare).
2.3.1. Analyses on C1q or BSA glycoconjugates-coated surfaces. The
running buﬀer for C1q and BSA glycoconjugates immobilization was
145 mM NaCl, 5 mM EDTA, 10 mM HEPES, pH 7.4. C1q andTable 1
Kinetic constants for the binding of C1q and its globular region to immobil
Immobilized ligand C1q
kon (M
1 s1) koﬀ (s
1) K
GlcNAc-BSA 4.7 ± 0.6 · 105 2.8 ± 0.3 · 103 5
Gal-BSA 1.1 ± 0.2 · 106 1.1 ± 0.1 · 103 1
GalNAc-BSA 6.5 ± 1.0 · 105 1.7 ± 0.2 · 103 2
ND: values not determined due to lack of binding.
Binding of C1q (2–20 nM) and its GR (0.3–2.4 lM) to BSA glycoconjugat
dissociation (koﬀ) rate constants were determined by global ﬁtting of the data u
The dissociation constants KD were determined from the koﬀ/kon ratios. The
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Fig. 1. SPR analysis of the interaction between BSA glycoconjugates
and human C1q or its GR. (A) Binding of 15 nM human C1q and (B)
of 1.5 lM GR to immobilized BSA glycoconjugates. (C) Binding of
BSA glycoconjugates to immobilized C1q. The speciﬁc binding signal
shown was obtained by subtracting the background signal (obtained
by injection of the protein or the glycoconjugate sample over a surface
with immobilized BSA). Other experimental conditions are described
in Section 2.BSA glycoconjugates were diluted to 50 lg/ml in 10 mM Na acetate,
pH 5.0, and to 25 lg/ml in 10 mM Na acetate, pH 4.0, respectively,
and immobilized onto a CM5 sensor chip (GE Healthcare) using the
BIAcore amine coupling kit. Binding of glycoconjugates to immobi-
lized C1q (19000 RU) and of C1q or its GR to immobilized glycocon-
jugates (5700–6500 RU) was measured at a ﬂow rate of 20 ll/min in
150 mM NaCl, 1 mM CaCl2, 20 mM HEPES, pH 7.4, containing
0.005% surfactant P20. Surfaces were regenerated by 3 injections of
10 ll of 2 M NaCl, 40 mM EDTA. The speciﬁc binding signal shown
was obtained by subtracting the background signal, routinely obtained
by injection of the sample over a surface with immobilized BSA. All
data were analyzed by global ﬁtting to a 1:1 Langmuir binding model
of both the association and dissociation phases for several concentra-
tions simultaneously, using the BIAevaluation 3.2 software (GE
Healthcare). All data presented were obtained with a statistic v2 va-
lue < 2. The apparent equilibrium dissociation constants (KD) were
calculated from the ratio of the dissociation and association rate con-
stants (koﬀ/kon). For competition analyses, binding of C1q (10 nM) to
immobilized GlcNAc-BSA and Gal-BSA (6500 RU) was recorded in
the running buﬀer containing 100 mM competitors, at a ﬂow rate of
20 ll/min.
2.3.2. Analyses using viable or apoptotic cells. HeLa cells were sus-
pended at 2.5 · 105 cells/ml in 140 mM NaCl, 5 mM KCl, 1 mM
MgCl2, 2.5 mM CaCl2, 25 mM HEPES, pH 7.4, containing 0.005%
surfactant P20, and passed over a C1q-coated surface at a ﬂow rate
of 10 ll/min. The surface was regenerated by injection of 10 mM
NaOH. The speciﬁc binding signal shown was obtained by subtracting
the background signal obtained by injection of the cell sample over an
activated–deactivated surface. Both untreated control cells and apop-
totic cells 2 h post-irradiation were incubated with increasing concen-
trations of DNase for 30 min at room temperature before injection
over immobilized C1q.
2.4. Electrophoretic mobility shift assay (EMSA)
DNA–protein complexes were prepared for gel shift assay as de-
scribed by Pananiyar et al. [16] with minor modiﬁcations. One hundred
ng of the Eco RI-digested Bluescript DNA plasmid (2950 bp) (Strata-
gene) were incubated with C1q or its GR for 60 min at 37 C in 20 ll
reaction buﬀer containing 20 mM Tris–HCl, 145 mM NaCl, 5 mM
CaCl2 (pH 7.4). The DNA–protein complexes were analysed by aga-
rose (1% w/v) gel electrophoresis in 40 mM Tris–acetate, pH 8, in
the absence of EDTA and visualized in the presence of SYBR safe
(Invitrogen) under UV light.3. Results
3.1. C1q interacts with neutral carbohydrates with high aﬃnity
through its globular region
The carbohydrate binding ability of human C1q was investi-
gated by SPR spectroscopy using immobilized BSA glycocon-
jugates. Control experiments showed that neither C1q nor its
GRs bound to a signiﬁcant extent to unmodiﬁed BSA used
as the immobilized ligand. In contrast, C1q was found to bind
to immobilized Gal-BSA, GlcNAc-BSA and GalNAc-BSA
(Fig. 1A) with KD values of 1.0, 5.9 and 2.6 nM, respectivelyized BSA glycoconjugates
C1q globular region
D (nM) kon (M
1 s1) koﬀ (s
1) KD (nM)
.9 ± 1.2 6.2 · 103 5.1 · 103 822
.0 ± 0.2 1.8 · 104 9.1 · 104 51
.6 ± 0.7 ND ND ND
es was measured as described in Section 2. The association (kon) and
sing a 1:1 Langmuir binding model (A + B AB, BIAevaluation 3.2).
values shown for C1q are means of two separate experiments.
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H. Paı¨dassi et al. / FEBS Letters 582 (2008) 3111–3116 3113(Table 1). We next tested the ability of the GR to interact with
the immobilized glycoconjugates. As illustrated in Fig. 1B, the
isolated C1q GR also bound to Gal-BSA and GlcNAc-BSA.
The association (kon) and dissociation (koﬀ) rate constants,
and the resulting KD were determined (Table 1) and compared
to those obtained for whole C1q. Whereas the koﬀ values were
in the same range in both cases, C1q exhibited signiﬁcantly
higher kon values than its GR. As a result, the KD values of
the interactions were higher for the GR (51 and 822 nM for
Gal-BSA and GlcNAc-BSA, respectively) compared to intact
C1q. This observation suggests that the interaction of the hex-
americ C1q molecule with carbohydrates involves simulta-
neous engagement of several globular domains, hence
strengthening binding through an avidity phenomenon. The
C1q–carbohydrate interaction was also observed in the reverse
conﬁguration, i.e. using BSA glycoconjugates as soluble li-
gands and immobilized C1q (Fig. 1C). In this case, KD values
of 139 nM and 370 nM were determined for GlcNAc-BSA and
GalNAc-BSA, respectively. In this conﬁguration, interaction
between C1q and Gal-BSA was also reproducibly detected,
but the binding signal was too weak to allow further
analysis.C
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Fig. 2. SPR analysis of the inhibition by hexoses and pentoses of the
interaction between C1q and BSA glycoconjugates. (A) Inhibition by
hexoses of C1q binding to immobilized GlcNAc-BSA and Gal-BSA.
(B) Inhibition by pentoses. The SPR response at the end of a 3-min
injection obtained in the absence of competitor was taken as 100%, and
the relative binding was calculated for each competitor at a concen-
tration of 100 mM. The data shown for GlcNAc-BSA represent the
mean value ± S.D. of two independent experiments (i.e. diﬀerent
samples and SPR sensor chips), whereas a representative experiment is
shown for Gal-BSA. (C) Dose-dependent inhibition of C1q binding to
GlcNAc-BSA by selected carbohydrates.3.2. Hexoses and pentoses compete for the C1q–carbohydrate
interaction
To gain further insights into the C1q–glycoconjugates inter-
action we tested the ability of a panel of soluble hexoses and
pentoses to compete for C1q binding to immobilized Glc-
NAc-BSA and Gal-BSA, as measured by SPR spectroscopy.
As illustrated in Fig. 2, inhibition values ranging from 35%
to 80% were observed using four diﬀerent hexoses (GlcNAc,
D-galactose, D-fucose, and maltose) and three pentoses (L-ri-
bose, L-arabinose, and D-ribose), each at a concentration of
100 mM. Interestingly, each of these carbohydrates inhibited
interaction with GlcNAc-BSA and Gal-BSA to similar extents.
As expected from our initial SPR measurements, GlcNAc and
D-Gal inhibited C1q binding to GlcNAc-BSA and Gal-BSA
(Fig. 2A). Interestingly, deoxy-D-ribose was the most eﬃcient
competitor, yielding over 70% inhibition at a concentration
of 100 mM (Fig. 2B). Since deoxy-D-ribose is the sugar compo-
nent of DNA, a known ligand of C1q [18], it is tempting to
hypothesize that C1q recognizes DNA through its pentose
units. Dose–response inhibition experiments were next con-
ducted using deoxy-D-ribose, mannose, or galactose as com-
petitors (Fig. 2C). C1q binding to GlcNac-BSA was
inhibited in a dose-dependent manner by deoxy-D-ribose
and, to a lesser extent, by galactose. Using mannose, only a
weak eﬀect was observed at high concentrations (>150 mM),
in keeping with other observations that C1q or its GR did
not interact signiﬁcantly with mannose-BSA immobilized on
a sensor chip (data not shown). The observation that deoxy-
D-ribose was a much better competitor than deoxy-L-ribose
(Fig. 2B) lends further credit to the hypothesis that C1q binds
DNA through its pentose moiety, considering that nucleic
acids only contain the D-form of pentoses.3.3. Binding of C1q GR to DNA is detected by EMSA
The above observations prompted us to further investigate
the ability of the C1q GR to interact with DNA. A EMSA
was used for this purpose, as previously described by Palaniyar
et al. for collectins SPA and SPD [16]. C1q or its GR wereincubated with a linear DNA plasmid and formation of
DNA–protein complexes was assessed by agarose gel electro-
phoresis. As depicted in Fig. 3A, both intact C1q and its GR
shifted DNA migration, indicating complex formation. All
DNA was complexed in the presence of 32 nM C1q. In con-
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H. Paı¨dassi et al. / FEBS Letters 582 (2008) 3111–3116 3115trast, only part of the DNA was shifted using 6.5 lMGR, and
a concentration of 13 lM was required to reach nearly com-
plete complex formation. This latter observation is fully con-
sistent with the fact that, in contrast with the native
hexameric C1q molecule, the C1q GR is monomeric and looses
binding avidity.
To investigate whether GR–carbohydrate interactions were
involved in DNA recognition by C1q, we tested the ability
of soluble deoxy-D-ribose to inhibit formation of DNA–pro-
tein complexes. As shown in Fig. 3B, the presence of a large
excess (100 mM) of deoxy-D-ribose partially impaired forma-
tion of DNA–GR complexes, as demonstrated by the in-
creased intensity of the band corresponding to uncomplexed
DNA. Mannose was used as a control, and no detectable
inhibitory eﬀect was observed at the same concentration.
3.4. DNA is involved in C1q binding to apoptotic cell surface
Taken together with previous data indicating that nucleic
acids are exposed at the cell surface at early stages of apoptosis
[13], our results strongly suggested that the ability of C1q to
recognize apoptotic cells may involve, at least in part, its lec-
tin-like activity towards the sugar moiety of DNA. To assess
the role of cell surface DNA in apoptotic cell recognition by
C1q we used a SPR-based assay developed in a recent study
[11]. HeLa cells were rendered apoptotic by UV-B irradiation,
and then both control cells and early apoptotic cells were al-
lowed to bind immobilized C1q with or without prior incuba-
tion with 400 Kunitz/ml DNase (Fig. 4A). Whereas DNase
treatment had no signiﬁcant eﬀect on the capture of viable cells
by C1q (Fig. 4A and C), it inhibited recognition of early apop-
totic cells (Fig. 4B). Inhibition was dose-dependent (Fig. 4C),
decreasing C1q binding by >40% at a DNase concentration
of 400 Kunitz/ml. This result provided direct evidence of the
implication of DNA as a target for C1q on the apoptotic cell
surface, shedding new light on the biological implication of
the lectin-like activity of C1q.4. Conclusion
This study provides evidence for a lectin-like activity of hu-
man C1q contributed by the globular region of the molecule.
This novel function may be physiologically relevant as it
may endow this protein with additional means to recognize
pathogens as well as apoptotic cells through interactions with
carbohydrates and/or DNA.
This conclusion is supported by the following observations:
(i) C1q recognizes BSA glycoconjugates speciﬁcally and avidly,
with KD values in the nM range; (ii) this interaction is also ob-
served using the isolated C1q GR; (iii) data from competition
assays indicate that C1q binds preferentially to deoxy-D-ri-
bose, a DNA component. (iv) The C1q GR binds to DNA,
as shown by an electrophoretic mobility shift assay; (v) DNase
treatment inhibits the capture of apoptotic cells by C1q in a
dose-dependent manner. Moreover, this study adds new in-
sights into the nature of C1q-DNA binding. We demonstrate
for the ﬁrst time that the peripheral globular region of the
C1q molecule is directly involved in DNA binding through
its lectin activity. Although the C1q orthologue in lamprey
which may be considered as the ancestor of vertebrate C1q,
is known as a GlcNAc binding lectin [22], this function hadnot yet been described for mammalian C1q. Thus, it appears
that the traditional portrait of C1q, considered to be a non-lec-
tin collagen defence molecule of the immune system, as op-
posed to the collectins SPA, SPD and mannose-binding
lectin (MBL), should be revised. This newly demonstrated lec-
tin activity broadens the recognition spectrum of the C1q mol-
ecule and emphasizes its particular ability to recognize targets
by ‘‘tethering’’ various ligands and receptors. One of the best
illustrations is the role of C1q in apoptotic cells recognition
and clearance. There is indeed growing evidence that the cell
death signature is composed of multiple molecules such as
DNA, calreticulin, phosphatidylserine and carbohydrates
[11–13,18,24,25]. Even if some of them are newly exposed on
the cell surface as a result of apoptosis, it is unlikely that they
might be perceived individually as a harmful signal. By its
capacity to bind several of these motifs, C1q would be a key
protein acting as a sensor for these potential ‘‘eat me’’ signals
and then triggering a speciﬁc immune machinery.References
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